Pharmacokinetics (PK), pharmacodynamics (PD) and integrated PK/PD modeling of a novel long acting FGF21 clinical candidate PF-05231023 in diet-induced obese and leptin-deficient obese mice

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Weng, Yan ^a   Chabot, Jeffrey R ^a   Bernardo, Barbara ^a   Yan, Qingyun ^a   Zhu, Yimin ^a   Brenner, Martin B ^a,b   Vage, Chandra ^a   Logan, Alison ^a   Calle, Roberto ^a   Talukdar, Saswata ^a  

^a PFIZER INC   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 21; PF 05231023; UNCLASSIFIED DRUG; FIBROBLAST GROWTH FACTOR; GLUCOSE BLOOD LEVEL; LEPTIN; MONOCLONAL ANTIBODY; PF-05231023;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIET INDUCED OBESITY; DRUG CLEARANCE; ELIMINATION HALF-LIFE; GLYCEMIC CONTROL; LEPTIN DEFICIENCY; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PHARMACODYNAMICS; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUME OF DISTRIBUTION; WEIGHT REDUCTION; ADVERSE EFFECTS; ANIMAL; BIOLOGICAL MODEL; DEFICIENCY; DIET; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MOUSE MUTANT; SUBCUTANEOUS DRUG ADMINISTRATION; TIME FACTOR;

MUS;

ADMINISTRATION, INTRAVENOUS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; BLOOD GLUCOSE; DIET; FIBROBLAST GROWTH FACTORS; GLUCOSE TOLERANCE TEST; INJECTIONS, SUBCUTANEOUS; LEPTIN; MALE; MICE, OBESE; MODELS, BIOLOGICAL; OBESITY; TIME FACTORS; WEIGHT LOSS;

EID: 84925708565     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0119104     Document Type: Article

References (38)

1. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, et al. FGF-21 as a novel metabolic regulator. J Clin Invest. 2005; 115: 1627-1635. PMID: 15902306
2. Gaich G, Chien JY, Fu H, Glass LC, Deeg MA, Holland WL, et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab. 2013; 18: 333-340. doi: 10.1016/j.cmet.2013.08.005 PMID: 24011069
3. Gimeno RE, Moller DE FGF21-based pharmacotherapy - potential utility for metabolic disorders. Trends Endocrinol Metab. 2014;
4. Coskun T, Bina HA, Schneider MA, Dunbar JD, Hu CC, Chen Y, et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology. 2008; 149: 6018-6027. doi: 10.1210/en.2008-0816 PMID: 18687777
5. Foltz IN, Hu S, King C, Wu X, Yang C, Wang W, et al. Treating diabetes and obesity with an FGF21-mimetic antibody activating the betaKlotho/FGFR1c receptor complex. Sci Transl Med. 2012; 4: 162ra153. doi: 10.1126/scitranslmed.3004690 PMID: 23197570
6. Huang J, Ishino T, Chen G, Rolzin P, Osothprarop TF, Retting K, et al. Development of a Novel Long-Acting Antidiabetic FGF21 Mimetic by Targeted Conjugation to a Scaffold Antibody. J Pharmacol Exp Ther. 2013; 346: 270-280. doi: 10.1124/jpet.113.204420 PMID: 23720456
7. Kharitonenkov A, Beals JM, Micanovic R, Strifler BA, Rathnachalam R, Wroblewski VJ, et al. Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319. PLoS One. 2013; 8: e58575. doi: 10.1371/journal.pone.0058575 PMID: 23536797
8. Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, Sivits G, et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes. 2009; 58: 250-259. doi: 10.2337/db08-0392 PMID: 18840786
9. Ding X, Boney-Montoya J, Owen BM, Bookout AL, Coate KC, Mangelsdorf DJ, et al. betaKlotho is required for fibroblast growth factor 21 effects on growth and metabolism. Cell Metab. 2012; 16: 387-393. doi: 10.1016/j.cmet.2012.08.002 PMID: 22958921
10. Ming AY, Yoo E, Vorontsov EN, Altamentova SM, Kilkenny DM, Rocheleau JV Dynamics and Distribution of Klothobeta (KLB) and fibroblast growth factor receptor-1 (FGFR1) in living cells reveal the fibroblast growth factor-21 (FGF21)-induced receptor complex. J Biol Chem. 2012; 287: 19997-20006. doi: 10.1074/jbc.M111.325670 PMID: 22523080
11. Goetz R, Beenken A, Ibrahimi OA, Kalinina J, Olsen SK, Eliseenkova AV, et al. Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol. 2007; 27: 3417-3428. PMID: 17339340
12. Goetz R, Mohammadi M Exploring mechanisms of FGF signalling through the lens of structural biology. Nat Rev Mol Cell Biol. 2013; 14: 166-180. doi: 10.1038/nrm3528 PMID: 23403721
13. Hager T, Spahr C, Xu J, Salimi-Moosavi H, Hall M Differential enzyme-linked immunosorbent assay and ligand-binding mass spectrometry for analysis of biotransformation of protein therapeutics: application to various FGF21 modalities. Anal Chem. 2013; 85: 2731-2738. doi: 10.1021/ac303203y PMID: 23373459
14. Micanovic R, Raches DW, Dunbar JD, Driver DA, Bina HA, Dickinson CD, et al. Different roles of N- and C- termini in the functional activity of FGF21. J Cell Physiol. 2009; 219: 227-234. doi: 10.1002/jcp. 21675 PMID: 19117008
15. Yie J, Hecht R, Patel J, Stevens J, Wang W, Hawkins N, et al. FGF21 N- and C-termini play different roles in receptor interaction and activation. FEBS Lett. 2009; 583: 19-24. doi: 10.1016/j.febslet.2008.11.023 PMID: 19059246
16. Veniant MM, Komorowski R, Chen P, Stanislaus S, Winters K, Hager T, et al. Long-acting FGF21 has enhanced efficacy in diet-induced obese mice and in obese rhesus monkeys. Endocrinology. 2012; 153: 4192-4203. doi: 10.1210/en.2012-1211 PMID: 22798348
17. Mu J, Pinkstaff J, Li Z, Skidmore L, Li N, Myler H, et al. FGF21 analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents. Diabetes. 2012; 61: 505-512. doi: 10.2337/db11-0838 PMID: 22210323
18. Reitman ML FGF21 mimetic shows therapeutic promise. Cell Metab. 2013; 18: 307-309. doi: 10.1016/j.cmet.2013.08.014 PMID: 24011067
19. Li P, Spann NJ, Kaikkonen MU, Lu M, Oh da Y, Fox JN, et al. NCoR repression of LXRs restricts macrophage biosynthesis of insulin-sensitizing omega 3 fatty acids. Cell. 2013; 155: 200-214. doi: 10.1016/j.cell.2013.08.054 PMID: 24074869
20. Lu M, Sarruf DA, Li P, Osborn O, Sanchez-Alavez M, Talukdar S, et al. Neuronal Sirt1 deficiency increases insulin sensitivity in both brain and peripheral tissues. J Biol Chem. 2013; 288: 10722-10735. doi: 10.1074/jbc.M112.443606 PMID: 23457303
21. Guo J, Hall KD Estimating the continuous-time dynamics of energy and fat metabolism in mice. PLoS Comput Biol. 2009; 5: e1000511. doi: 10.1371/journal.pcbi.1000511 PMID: 19763167
22. Hall KD What is the required energy deficit per unit weight loss? Int J Obes (Lond). 2008; 32: 573-576. PMID: 17848938
23. Tschop MH, Speakman JR, Arch JR, Auwerx J, Bruning JC, Chan L, et al. A guide to analysis of mouse energy metabolism. Nat Methods. 2012; 9: 57-63. doi: 10.1038/nmeth.1806 PMID: 22205519
24. Fisher FM, Kleiner S, Douris N, Fox EC, Mepani RJ, Verdeguer F, et al. FGF21 regulates PGC-1alpha and browning of white adipose tissues in adaptive thermogenesis. Genes Dev. 2012; 26: 271-281. doi: 10.1101/gad.177857.111 PMID: 22302939
25. Lin Z, Zhou Z, Liu Y, Gong Q, Yan X, Xiao J, et al. Circulating FGF21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in Chinese. PLoS One. 2011; 6: e18398. doi: 10.1371/journal.pone.0018398 PMID: 21525989
26. Stein S, Bachmann A, Lossner U, Kratzsch J, Bluher M, Stumvoll M, et al. Serum levels of the adipokine FGF21 depend on renal function. Diabetes Care. 2009; 32: 126-128. doi: 10.2337/dc08-1054 PMID: 18840768
27. Kharitonenkov A, Larsen P FGF21 reloaded: challenges of a rapidly growing field. Trends Endocrinol Metab. 2011; 22: 81-86. doi: 10.1016/j.tem.2010.11.003 PMID: 21194964
28. Fon Tacer K, Bookout AL, Ding X, Kurosu H, John GB, Wang L, et al. Research resource: Comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol Endocrinol. 2010; 24: 2050-2064. doi: 10.1210/me.2010-0142 PMID: 20667984
29. Veniant MM, Hale C, Helmering J, Chen MM, Stanislaus S, Busby J, et al. FGF21 promotes metabolic homeostasis via white adipose and leptin in mice. PLoS One. 2012; 7: e40164. doi: 10.1371/journal. pone.0040164 PMID: 22792234
30. Kliewer SA, Mangelsdorf DJ Fibroblast growth factor 21: from pharmacology to physiology. Am J Clin Nutr. 2010; 91: 254S-257S. doi: 10.3945/ajcn.2009.28449B PMID: 19906798
31. Holland WL, Adams AC, Brozinick JT, Bui HH, Miyauchi Y, Kusminski CM, et al. An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice. Cell Metab. 2013; 17: 790-797. doi: 10.1016/j.cmet.2013.03.019 PMID: 23663742
32. Lin Z, Tian H, Lam KS, Lin S, Hoo RC, Konishi M, et al. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab. 2013; 17: 779-789. doi: 10.1016/j.cmet.2013.04.005 PMID: 23663741
33. Sarruf DA, Thaler JP, Morton GJ, German J, Fischer JD, Ogimoto K, et al. Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats. Diabetes. 2010; 59: 1817-1824. doi: 10.2337/db09-1878 PMID: 20357365
34. Adams AC, Halstead CA, Hansen BC, Irizarry AR, Martin JA, Myers SR, et al. LY2405319, an Engineered FGF21 Variant, Improves the Metabolic Status of Diabetic Monkeys. PLoS One. 2013; 8: e65763. PMID: 23823755
35. Adams AC, Coskun T, Rovira AR, Schneider MA, Raches DW, Micanovic R, et al. Fundamentals of FGF19 & FGF21 action in vitro and in vivo. PLoS One. 2012; 7: e38438. doi: 10.1371/journal.pone.0038438 PMID: 22675463
36. Kim HW, Lee JE, Cha JJ, Hyun YY, Kim JE, Lee MH, et al. Fibroblast growth factor 21 improves insulin resistance and ameliorates renal injury in db/db mice. Endocrinology. 2013; 154: 3366-3376. doi: 10.1210/en.2012-2276 PMID: 23825123
37. Wu AL, Coulter S, Liddle C, Wong A, Eastham-Anderson J, French DM, et al. FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways. PLoS One. 2011; 6: e17868. doi: 10.1371/journal.pone.0017868 PMID: 21437243
38. Owen BM, Ding X, Morgan DA, Coate KC, Bookout AL, Rahmouni K, et al. FGF21 Acts Centrally to Induce Sympathetic Nerve Activity, Energy Expenditure, and Weight Loss. Cell Metab. 2014;